More News

21 Apr 2021 Johnson & Johnson COVID-19 Vaccine Roll-out to Resume in Europe Following European Medicines Agency (EMA) Review
20 Apr 2021 Vertex Pharmaceuticals and CRISPR Therapeutics Amend Collaboration for Development, Manufacturing and Commercialization of CTX001™ in Sickle Cell Disease and Beta Thalassemia
20 Apr 2021 Steba Biotech Treats First Patient in Pivotal ENLIGHTED Study of Padeliporfin ImPACT in Low Grade Upper Tract Urothelial Cancer
15 Apr 2021 New protein degradation centre to lead drug discovery revolution
14 Apr 2021 BERG Announces Oncology Pipeline Advancements And Biomarker Developments For Clinical Decision Support In Breast Cancer At AACR
09 Apr 2021 Sanofi acquires Tidal Therapeutics, adding innovative mRNA-based research platform with applications in oncology, immunology, and other disease areas
06 Apr 2021 Sorrento Enters Into Merger Agreement to Acquire Late-Stage Oncology Company ACEA Therapeutics
05 Apr 2021 Cidara Therapeutics Announces Agreement with Janssen to Develop and Commercialize AVCs for the Prevention and Treatment of Influenza
02 Apr 2021 Arbutus Biopharma, X-Chem and Proteros biostructures Enter into a Pan-Coronavirus Discovery Research and License Agreement
02 Apr 2021 AbCellera and Gilead Sciences Announce New Multi-Year, Multi-Target Antibody Discovery Collaboration
02 Apr 2021 Eloxx Pharmaceuticals Acquires Zikani Therapeutics
30 Mar 2021 Leiden University Medical Center and Ixaka enter collaboration to strengthen knowledge of cell therapy candidate REX-001
30 Mar 2021 Novartis expands targeted radioligand therapy pipeline with in-license for compounds targeting Fibroblast Activation Protein (FAP)
30 Mar 2021 BridGene Biosciences Announces Research Collaboration with Takeda to Discover Small Molecule Drugs for "Undruggable" Targets
23 Mar 2021 PhoreMost closes £33M ($46M) Series B financing
22 Mar 2021 SemaThera Enters into a Research Collaboration and Exclusive License Agreement with Roche
18 Mar 2021 Boston Pharmaceuticals Enters into Unique Multi-Year Out-License and Option Agreement with GSK for the Advancement of Multiple Pre-Phase 2 Programs
17 Mar 2021 Amphista Therapeutics raises $53M in oversubscribed Series B round to advance next generation targeted protein degradation assets
17 Mar 2021 Amathus Therapeutics Signs Strategic Collaboration With Merck to Develop Treatments for Neurodegenerative Diseases
17 Mar 2021 Seekyo raises over €650,000 from business angels and Bpifrance
17 Mar 2021 DZNE and Eisai enter into research collaboration agreement aiming for novel drug discovery for neurodegenerative disorders
16 Mar 2021 GBT Expands Sickle Cell Disease Pipeline with Exclusive In-license of Two Novel Small Molecule Programs from Sanofi S.A.
16 Mar 2021 Perception Neuroscience And Otsuka Pharmaceutical Announce Collaboration On Development Of PCN-101 (R-ketamine) In Japan For Treatment-of Depressive Disorders
16 Mar 2021 Boehringer Ingelheim and The Lieber Institute for Brain Development to Collaborate to Develop Centrally Acting COMT Inhibitors for Treatment of Neuropsychiatric Disorders
15 Mar 2021 Genevant Sciences Announces Global Collaboration and License Agreement with Takeda to Develop Novel Nucleic Acid Therapeutics for Liver Fibrosis

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2021 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up